Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis

Kidney International

Volumn 76, Issue 2, 2009, Pages 178-182

  Gattone II, Vincent H ^a   Sinders, Rachel M ^a   Hornberger, Troy A ^b   Robling, Alexander G ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

MTOR; Nephronophthisis; Rapamycin; Renal cysts

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; GENE MUTATION; KIDNEY CYST; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; MOUSE; NEPHRONOPHTHISIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SLOW RELEASE FORMULATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; CARRIER PROTEINS; CYSTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; KIDNEY DISEASES, CYSTIC; KIDNEY FUNCTION TESTS; MALE; MICE; MICE, INBRED STRAINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIROLIMUS;

EID: 67649872366     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.147     Document Type: Article

References (14)

1. Hildebrandt F, Zhou W. Nephronophthisis-associated ciliopathies. J Am Soc Nephrol 2007; 18: 1855-1871.
2. Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 2007; 261: 17-31.
3. Omran H, Häffner K, Burth S et al. Human adolescent nephronophthisis: gene locus synteny with polycystic kidney disease in pcy mice. J Am Soc Nephrol 2001; 12: 107-113.
4. Olbrich H, Fliegauf M, Hoefele J et al. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet 2003; 34: 455-459.
5. Takahashi H, Calvet JP, Dittemore-Hoover D et al. A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrol 1991; 1: 980-989.
6. Gattone VH, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326.
7. Tao Y, Kim J, Schrier RW et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51.
8. Wahl PR, Serra AL, Le Hir M et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604.
9. Wu M, Wahl PR, Le Hir M et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259.
10. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471.
11. Qian Q, Du H, King BF et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19: 631-638.
12. Omori S, Hida M, Fujita H et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006; 17: 1604-1614.
13. Grozinsky-Glasberg S, Franchi G, Teng M et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008; 87: 168-181.
14. Reichardt W, Romaker D, Becker A et al. Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD. MAGMA (in press).